Xencor, Inc.

Xencor, Inc. develops engineered monoclonal antibody and cytokine therapeutics for cancer and autoimmune diseases. Products include Sotrovimab for COVID-19, Ultomiris for paroxysmal nocturnal hemoglobinuria, Monjuvi for diffuse large B-cell lymphoma, and Plamotamab and Vudalimab for non-Hodgkin lymphoma and prostate cancer. The company also develops XmAb306, XmAb104, XmAb564, AMG 509, XmAb819, XmAb541, and XmAb662 for various cancers and autoimmune diseases. Additionally, Xencor develops VIR-3434 and VIR-2482 for hepatitis B virus infection.

Overview

Sector

Biotechnology

Target Price

0.0 USD

Current Price

7.8 USD

Potential

-100%

Strengths

Price to book ratio (0.79) is lower than the sector mean (24.44).

Weaknesses

With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
Analysts expect revenues to decline in the coming year.
The company has high debt. Net Debt to EBITDA Ratio (100.00) is higher than the sector mean.
The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (6.02%).
EBITDA Margin (0.00%) appears relatively low.

Key Financial Data

Indicator	Value
PER	100.0
EV/EBITDA	100.0
Price/Free Cash Flow'	100.0
ROIC	-%
Net Debt/EBITDA	100.0